Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
US-12595307-B2 · Apr 7, 2026 · US
This page is not indexed by search engines while we improve data quality.
Nantbio Inc — Human Necessities
Nantbio Inc holds 101 patents in Human Necessities, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Nantbio Inc |
| Technology | Human Necessities |
| Patents in slice | 101 |
| Recent patents in slice | 45 |
| First year | 2018 |
| Last year | 2026 |
Representative patents
Notable publications linking Nantbio Inc to Human Necessities.
Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
US-12595307-B2 · Apr 7, 2026 · US
Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
US-12595307-B2 · Apr 7, 2026 · US
Recombinant erIL-15 NK cells
US-12516093-B2 · Jan 6, 2026 · US
Recombinant erIL-15 NK cells
US-12516093-B2 · Jan 6, 2026 · US
Recent filings
Latest patents from Nantbio Inc in Human Necessities.
Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
US-12595307-B2 · Apr 7, 2026 · US
Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
US-12595307-B2 · Apr 7, 2026 · US
Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
US-12595307-B2 · Apr 7, 2026 · US
Recombinant erIL-15 NK cells
US-12516093-B2 · Jan 6, 2026 · US
Recombinant erIL-15 NK cells
US-12516093-B2 · Jan 6, 2026 · US
Related pages
Navigate to parent entity pages.